Börse:

Revance Therapeutics, Inc.

[WKN: A1XD3D | ISIN: US7613301099]

3,650$ 0,27%

Echtzeit-Aktienkurs Revance Therapeutics, Inc.

Bid: Ask:

Nachrichten zur Revance Therapeutics, Inc. Aktie

» Nachrichtenticker öffnen

REVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, IIPR, FTAI, and Revance and Encourages Investors to Contact the Firm

NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

RVNC STOCK NEWS: Robbins LLP Reminds Revance Therapeutics, Inc. Investors of the Pending Lead Plaintiff Deadline – March 4, 2025

Robbins LLP is Investigating Allegations that Revance Therapeutics, Inc. (RVNC) Misled Investors Regarding its Business Prospects…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against IIPR, AstraZeneca, FTAI, and Revance and Encourages Investors to Contact the Firm

NEW YORK, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors – Contact Levi & Korsinsky

NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc.…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, AstraZeneca, FTAI, and Revance and Encourages Investors to Contact the Firm

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioAge, Caribou, FTAI, and Revance and Encourages Investors to Contact the Firm

NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights…

RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Jan. 26, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law…

March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNC

NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Revance Therapeutics, Inc.…

Revance Therapeutics plunges after Crown Labs cuts takeover price in half

…

Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares

…

How Much Upside is Left in Revance Therapeutics (RVNC)? Wall Street Analysts Think 55.02%

The consensus price target hints at a 55% upside potential for Revance Therapeutics (RVNC). While empirical research shows that this…

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

…

Revance Therapeutics Inc. (RVNC) Q1 2024 Earnings Call Transcript

…

Revance Therapeutics president sells over $46k in company stock By Investing.com

Revance Therapeutics president sells over $46k in company stock…

Revance Therapeutics CFO sells over $47,000 in company stock By Investing.com

Revance Therapeutics CFO sells over $47,000 in company stock…

Earnings call: Revance Therapeutics reports robust growth in 2023 By Investing.com

Earnings call: Revance Therapeutics reports robust growth in 2023…

Revance Therapeutics Inc. (RVNC) Q4 2023 Earnings Call Transcript

…

‹
1
›